查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470686

昼夜节律睡眠治疗市场：依地区（北美、欧洲、亚太地区、拉丁美洲、中东非洲）：全球产业分析、规模、占有率、成长、趋势、预测，2024-2031年

Circadian Rhythm Sleep Treatment Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 310 Pages | 商品交期: 2-5个工作天内

价格
简介目录

由于人们对睡眠障碍的认识不断提高以及睡眠医学的进步，昼夜节律睡眠治疗市场是一个快速发展的领域。 这个市场包括各种旨在解决影响睡眠-觉醒週期和整体健康的体内生理时钟紊乱的治疗方法和治疗方法。 本报告深入探讨了 2024 年至 2031 年昼夜节律睡眠治疗市场的成长动力、潜在课题和新兴趋势，为利害关係人和医疗保健专业人士提供了宝贵的见解。

预计全球昼夜节律睡眠治疗市场将在预测期内稳定成长，2024年至2031年的复合年增长率为4.7%。 该市场预计将从 2024 年的 7.84 亿美元成长到 2031 年底的 11 亿美元。

关键见解

  • 预计市场价值（2024 年）：7.84 亿美元
  • 预计市值（2031 年）：11 亿美元
  • 全球市场成长率（2024-2031 年复合年增长率）：4.7%

昼夜节律睡眠治疗市场 - 报告范围：

昼夜节律睡眠障碍 (CRSD) 会影响自然的睡眠-觉醒週期，并且由于现代生活方式的改变和人造光暴露的增加而变得越来越常见。 这些疾病包括睡眠时相延迟障碍 (DSPD)、睡眠时相提前障碍 (ASPD)、轮班工作障碍和时差障碍。 本报告探讨了可用的治疗方法，包括光疗、褪黑激素补充剂、行为治疗和药理学方法。

市场驱动因素：

昼夜节律睡眠治疗市场的成长受到多种因素的推动。 提高人们对睡眠健康重要性及其对整体健康影响的认识是一个关键驱动因素。 此外，由于现代生活方式、压力和工作相关因素，睡眠障碍的盛行率日益增加，这也推动了对有效治疗的需求。 睡眠技术和个人化医疗的进步正在实现更准确的诊断和量身定制的治疗方法，进一步推动市场成长。 穿戴式睡眠追踪设备和行动健康应用程式的日益普及也有助于提高对睡眠障碍的认识和管理。

市场限制因素：

儘管存在成长潜力，但昼夜节律睡眠治疗市场面临一些课题。 某些治疗方法的高成本，尤其是那些涉及先进技术或个人化方法的治疗方法，可能会抑制人们的吸收。 在某些地区，获得专业睡眠诊所和专家的机会有限也可能限制市场成长。 此外，一般人群缺乏对昼夜节律紊乱的认识可能会妨碍早期诊断和早期治疗。 对药物治疗潜在副作用和对助眠剂的依赖的担忧也可能影响消费者的信心。

市场机会：

昼夜节律睡眠治疗市场提供了大量的创新和扩张机会。 公司可以专注于开发更容易获得和负担得起的治疗选择，例如光疗设备和睡眠追踪可穿戴设备。 睡眠专家和科技公司的共同努力可能会带来更加整合和用户友好的解决方案。 远距医疗和虚拟咨询的兴起为扩大睡眠治疗服务的覆盖范围提供了机会，特别是在偏远地区。 此外，提高大众对睡眠健康的认识活动将有助于早期诊断并鼓励采取预防措施，最终促进市场成长。

目录

第 1 章执行摘要

第二章市场介绍

  • 市场范围/分类
  • 市场定义/范围/限制

第三章全球昼夜节律睡眠治疗市场的主要趋势

  • 影响市场的主要趋势
  • 产品创新趋势
  • 创新与新产品
  • 区域疾病概述和流行病学（患病率数据）

第 4 章全球昼夜节律睡眠治疗市场的关键成功因素

  • 产品采用/认知度分析
  • 产品特性与故障矩阵

第五章全球昼夜节律睡眠治疗市场 - 价格分析

  • 区域价格分析
  • 价格明细
    • 製造商等级定价
    • 经销商级定价
  • 世界平均价格分析基准

第六章全球昼夜节律睡眠治疗市场需求分析与预测

  • 过去的市场价值（金额）分析，2019-2023 年
  • 2024-2031 年当前及未来市场价值（金额）预测
  • 年成长趋势分析

第七章全球昼夜节律睡眠治疗市场现况

  • 主要规定
  • 宏观经济因素
  • 预测因子 - 相关性和影响
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会分析

第 8 章全球昼夜节律睡眠治疗市场分析及依治疗类型预测

  • 简介/主要发现
  • 过去的市场规模（金额）与数量分析，2019-2023 年
  • 2024-2031 年市场规模（金额）与数量预测
    • 设备
      • 处理设备
        • 灯箱
        • 檯灯
        • 遮光罩
        • 黎明模拟器
      • 诊断设备
        • 体动记录感测器
        • 手腕与手带式体动记录仪
        • 穿戴式体动记录仪
        • 多导睡眠监测装置
        • 固定式多导睡眠监测装置
        • 便携式多导睡眠监测仪
    • 药物
      • 苯二氮平类药物
      • 非苯二氮平类安眠药
      • 食慾素受体拮抗剂
      • 褪黑激素受体激动剂
    • 时间疗法
  • 依治疗类型进行市场吸引力分析

第 9 章全球昼夜节律睡眠治疗市场依疾病分析与预测

  • 简介/主要发现
  • 过去的市场规模（金额）分析，2019-2023 年
  • 2024-2031 年市场规模（金额）预测
    • 睡眠时相延迟症候群 (DSPS)
    • 高阶睡眠阶段症候群 (ASPS)
    • 非 24 小时睡眠觉醒症候群
    • 睡眠/觉醒不规律 (ISWD)
    • 轮班工作混乱
    • 时差反应
  • 依残障状况进行市场吸引力分析

第10章全球昼夜节律睡眠治疗市场分析及通路预测

  • 简介/主要发现
  • 过去的市场规模（金额）分析，2019-2023 年
  • 2024-2031 年市场规模（金额）预测
    • 向机构投资人销售
      • 居家照护环境
      • 健康中心和水疗中心
      • 睡眠测试中心
      • 专科诊所
      • 医院
    • 零售销售
      • 零售药局
      • 药局
      • 线上销售
  • 依分销管道划分的市场吸引力分析

第11章全球昼夜节律睡眠治疗市场分析及地区预测

  • 简介/主要发现
  • 过去的市场规模（金额）与数量分析，2019-2023 年
  • 2024-2031 年市场规模（金额）与数量预测
    • 北美
    • 拉丁美洲
    • 欧洲
    • 南亚
    • 东亚
    • 大洋洲
    • 中东和非洲
  • 依地区划分的市场吸引力分析

第十二章北美昼夜节律睡眠治疗市场分析与预测

第十三章拉丁美洲昼夜节律睡眠治疗市场分析与预测

第14章欧洲昼夜节律睡眠治疗市场分析与预测

第十五章东亚昼夜节律睡眠治疗市场分析与预测

第十六章南亚昼夜节律睡眠治疗市场分析与预测

第十七章大洋洲昼夜节律睡眠治疗市场分析与预测

第十八章中东与非洲昼夜节律睡眠治疗市场分析与预测

第19章竞争分析

  • 竞争对手仪表板
  • 有竞争力的价格分析
  • 竞争基准
  • 以竞争对手划分的毛利分析
  • 竞赛的发展
  • 衝突详情
    • Vanda Pharmaceuticals Inc.
    • Natus Medical Incorporated
    • Compumedics Ltd.
    • Teva Pharmaceutical Industries Ltd
    • Takeda Pharmaceutical Company
    • Koninklijke Philips NV
    • Mylan NV
    • Fitbit, Inc
    • Garmin Ltd
    • Lucimed SA
    • RedMed Inc.
    • Compass Health Brands（Carex Health）
    • Beurer GmbH
    • Samarit Medical AG
    • Lanaform NV

第 20 章先决条件与使用的缩写

第21章研究方法

简介目录
Product Code: PMRREP27310

The circadian rhythm sleep treatment market is a rapidly evolving sector, driven by increasing awareness about sleep disorders and advancements in sleep medicine. This market encompasses various treatments and therapies designed to address disruptions in the body's internal clock, affecting sleep-wake cycles and overall health. This report delves into the key factors driving growth, potential challenges, and emerging trends in the circadian rhythm sleep treatment market from 2024 through 2031, providing valuable insights for stakeholders and healthcare professionals.

The global circadian rhythm sleep treatment market is expected to experience steady growth during the forecast period, with a projected CAGR of 4.7% from 2024 to 2031. The market is estimated to expand from a value of USD 784 million in 2024 to USD 1.1 billion by the end of 2031.

Key Insights:

  • Estimated Market Value (2024): USD 784 million
  • Projected Market Value (2031): USD 1.1 Billion
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.7%

Circadian Rhythm Sleep Treatment Market - Report Scope:

Circadian rhythm sleep disorders (CRSDs) are becoming more prevalent due to modern lifestyle changes and increased exposure to artificial light, impacting the natural sleep-wake cycle. These disorders include delayed sleep phase disorder (DSPD), advanced sleep phase disorder (ASPD), shift work disorder, and jet lag disorder. The report explores the scope of these treatments, covering various therapies such as light therapy, melatonin supplements, behavioral therapy, and pharmacological approaches.

Market Growth Drivers:

The growth of the circadian rhythm sleep treatment market is driven by several factors. Increasing awareness about the importance of sleep health and its impact on overall well-being is a significant driver. Additionally, the rising prevalence of sleep disorders due to modern lifestyles, stress, and work-related factors fuels the demand for effective treatments. Advances in sleep technology and personalized medicine are enabling more accurate diagnosis and tailored treatment approaches, further boosting market growth. The growing adoption of wearable sleep tracking devices and mobile health applications also contributes to the increased awareness and management of sleep disorders.

Market Restraints:

Despite its growth potential, the circadian rhythm sleep treatment market faces several challenges. High costs associated with some treatments, especially those involving advanced technology or personalized approaches, can deter widespread adoption. Limited access to specialized sleep clinics and professionals in certain regions may also restrict market growth. Additionally, lack of awareness about circadian rhythm disorders among the general population can hinder early diagnosis and treatment. Concerns about the potential side effects of pharmacological treatments and dependency on sleep aids can also affect consumer confidence.

Market Opportunities:

The circadian rhythm sleep treatment market presents numerous opportunities for innovation and expansion. Companies can focus on developing more accessible and affordable treatment options, such as light therapy devices and sleep-tracking wearables. Collaborative efforts between sleep experts and technology companies can lead to more integrated and user-friendly solutions. The rise of telehealth and virtual consultations offers an opportunity to expand access to sleep treatment services, especially in remote areas. Furthermore, increasing public awareness campaigns about sleep health can drive early diagnosis and encourage preventive measures, ultimately contributing to market growth.

Key Questions Addressed in the Report:

  • What is the Expected Value CAGR of the Circadian Rhythm Sleep Treatment Market?
  • What is the Revenue Size of the Global Circadian Rhythm Sleep Treatment Market as of 2024-end?
  • Which Region Held the Largest Market Share in 2024?
  • Who are the Key Players in the Global Circadian Rhythm Sleep Treatment Market?
  • What are the Most Effective Treatments for Circadian Rhythm Sleep Disorders?

Competitive Landscape and Business Strategies:

The competitive landscape in the circadian rhythm sleep treatment market features a mix of established pharmaceutical companies and innovative tech startups. Key players like Jazz Pharmaceuticals, Philips Healthcare, and Fitbit offer a range of sleep treatment solutions, from pharmacological therapies to wearable devices. Jazz Pharmaceuticals focuses on developing medications for sleep disorders, including narcolepsy and insomnia. Philips Healthcare offers a variety of sleep-related devices, such as light therapy and continuous positive airway pressure (CPAP) machines. Fitbit, a leader in wearable technology, has integrated sleep tracking features into its fitness devices, enabling users to monitor and improve their sleep patterns.

Key Companies Profiled:

  • Jazz Pharmaceuticals
  • Philips Healthcare
  • Fitbit
  • ResMed
  • Takeda Pharmaceuticals
  • Vanda Pharmaceuticals
  • Garmin
  • Zeo Health
  • Beddit
  • Casio Computer Co., Ltd.
  • Medtronic

Circadian Rhythm Sleep Treatment Market Segmentation:

By Treatment Type:

  • Light Therapy
  • Melatonin Supplements
  • Behavioral Therapy
  • Pharmacological Treatment

By Distribution Channel:

  • Hospitals and Sleep Clinics
  • Online Retail
  • Specialty Pharmacies

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Disorder Roadmap Analysis
  • 1.5. Analysis and Recommendations

2. Market Introduction

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Global Circadian Rhythm Sleep Treatment Market Key Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation Trends
  • 3.3. Innovations & New Launches
  • 3.4. Disease Overview and Epidemiology (Prevalence Data), by Region

4. Global Circadian Rhythm Sleep Treatment Market Key Success Factors

  • 4.1. Product Adoption / Awareness Analysis
  • 4.2. Product Features Vs. Disorder Matrix

5. Global Circadian Rhythm Sleep Treatment Market - Pricing Analysis

  • 5.1. Regional Pricing Analysis
  • 5.2. Pricing Break-Up
    • 5.2.1. Manufacturer Level Pricing
    • 5.2.2. Distributor Level Pricing
  • 5.3. Global Average Pricing Analysis Benchmark

6. Global Circadian Rhythm Sleep Treatment Market Demand Analysis 2019-2023 and Forecast, 2024-2031

  • 6.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 6.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
  • 6.3. Y-o-Y Growth Trend Analysis

7. Global Circadian Rhythm Sleep Treatment Market Context

  • 7.1. Key Regulations
  • 7.2. Macro-Economic Factors
  • 7.3. Forecast Factors - Relevance & Impact
  • 7.4. Market Dynamics
    • 7.4.1. Drivers
    • 7.4.2. Restraints
    • 7.4.3. Opportunity Analysis

8. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Treatment Type

  • 8.1. Introduction/Key Finding
    • 8.1.1. Market Size (US$ Mn) and Volume Share Analysis By Treatment Type
    • 8.1.2. Y-o-Y Growth Analysis By Treatment Type
  • 8.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Treatment Type, 2019-2023
  • 8.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Treatment Type, 2024-2031
    • 8.3.1. Devices
      • 8.3.1.1. Therapeutic Devices
        • 8.3.1.1.1. Light Box
        • 8.3.1.1.2. Desk Lamps
        • 8.3.1.1.3. Light Visor
        • 8.3.1.1.4. Dawn Simulator
      • 8.3.1.2. Diagnostic Devices
        • 8.3.1.2.1. Actigraphy Sensors
        • 8.3.1.2.1.1. Wrist and Hand band Actigraphy Devices
        • 8.3.1.2.1.2. Wearable Actigraphy Devices
        • 8.3.1.2.2. Polysomnography Devices
        • 8.3.1.2.2.1. Fixed Polysomnography Devices
        • 8.3.1.2.2.2. Portable Polysomnography Devices
    • 8.3.2. Drugs
      • 8.3.2.1. Benzodiazepines
      • 8.3.2.2. Nonbenzodiazepine hypnotics
      • 8.3.2.3. Orexin receptor antagonists
      • 8.3.2.4. Melatonin receptor agonist
    • 8.3.3. Chronotherapy
  • 8.4. Market Attractiveness Analysis By Treatment Type

9. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Disorder

  • 9.1. Introduction/Key Finding
    • 9.1.1. Market Size (US$ Mn) Analysis By Disorder
    • 9.1.2. Y-o-Y Growth Analysis By Disorder
  • 9.2. Historical Market Size (US$ Mn) Analysis By Disorder , 2019-2023
  • 9.3. Market Size (US$ Mn) Forecast By Disorder , 2024-2031
    • 9.3.1. Delayed Sleep Phase Syndrome (DSPS)
    • 9.3.2. Advanced Sleep Phase Syndrome (ASPS)
    • 9.3.3. Non-24-h Sleep-Wake Syndrome
    • 9.3.4. Irregular Sleep-Wake Disorder (ISWD)
    • 9.3.5. Shift Work Disorder
    • 9.3.6. Jet Lag
  • 9.4. Market Attractiveness Analysis By Disorder

10. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

  • 10.1. Introduction/Key Finding
    • 10.1.1. Market Size (US$ Mn) Analysis By Distribution Channel
    • 10.1.2. Y-o-Y Growth Analysis By Distribution Channel
  • 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
  • 10.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2024-2031
    • 10.3.1. Institutional Sales
      • 10.3.1.1. Home Care Settings
      • 10.3.1.2. Wellness Centers & Spa
      • 10.3.1.3. Sleep Testing Centers
      • 10.3.1.4. Specialty Clinics
      • 10.3.1.5. Hospitals
    • 10.3.2. Retail Sales
      • 10.3.2.1. Retail Pharmacies
      • 10.3.2.2. Drug Stores
      • 10.3.2.3. Online Sales
  • 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Region

  • 11.1. Introduction/Key Finding
    • 11.1.1. Market Size (US$ Mn) and Volume Share Analysis By Region
    • 11.1.2. Y-o-Y Growth Analysis By Region
  • 11.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Region, 2019-2023
  • 11.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Region, 2024-2031
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. South Asia
    • 11.3.5. East Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa
  • 11.4. Market Attractiveness Analysis By Region

12. North America Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 12.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Treatment Type
    • 12.3.3. By Disorder
    • 12.3.4. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Treatment Type
    • 12.4.3. By Disorder
    • 12.4.4. By Distribution Channel
  • 12.5. Drivers and Restraints: Impact Analysis
  • 12.6. Key Market Participants - Intensity Mapping

13. Latin America Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 13.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 13.3.1. By Country
      • 13.3.1.1. Brazil
      • 13.3.1.2. Mexico
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Treatment Type
    • 13.3.3. By Disorder
    • 13.3.4. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Treatment Type
    • 13.4.3. By Disorder
    • 13.4.4. By Distribution Channel
  • 13.5. Drivers and Restraints: Impact Analysis
  • 13.6. Key Market Participants - Intensity Mapping

14. Europe Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 14.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 14.3.1. By Country
      • 14.3.1.1. U.K.
      • 14.3.1.2. Germany
      • 14.3.1.3. France
      • 14.3.1.4. Italy
      • 14.3.1.5. Spain
      • 14.3.1.6. BENELUX
      • 14.3.1.7. Nordic
      • 14.3.1.8. Poland
      • 14.3.1.9. Rest of Europe
    • 14.3.2. By Treatment Type
    • 14.3.3. By Disorder
    • 14.3.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Treatment Type
    • 14.4.3. By Disorder
    • 14.4.4. By Distribution Channel
  • 14.5. Drivers and Restraints: Impact Analysis
  • 14.6. Key Market Participants - Intensity Mapping

15. East-Asia Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 15.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
      • 15.3.1.4. Rest of East Asia
    • 15.3.2. By Treatment Type
    • 15.3.3. By Disorder
    • 15.3.4. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Treatment Type
    • 15.4.3. By Disorder
    • 15.4.4. By Distribution Channel
  • 15.5. Drivers and Restraints: Impact Analysis
  • 15.6. Key Market Participants - Intensity Mapping

16. South Asia Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 16.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Thailand
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Indonesia
      • 16.3.1.5. Philippines
      • 16.3.1.6. Rest of South Asia
    • 16.3.2. By Treatment Type
    • 16.3.3. By Disorder
    • 16.3.4. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Treatment Type
    • 16.4.3. By Disorder
    • 16.4.4. By Distribution Channel
  • 16.5. Drivers and Restraints: Impact Analysis
  • 16.6. Key Market Participants - Intensity Mapping

17. Oceania Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 17.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Treatment Type
    • 17.3.3. By Disorder
    • 17.3.4. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Treatment Type
    • 17.4.3. By Disorder
    • 17.4.4. By Distribution Channel
  • 17.5. Drivers and Restraints: Impact Analysis
  • 17.6. Key Market Participants - Intensity Mapping

18. MEA Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
  • 18.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Iran
      • 18.3.1.3. Israel
      • 18.3.1.4. Turkey
      • 18.3.1.5. Rest of MEA
    • 18.3.2. By Treatment Type
    • 18.3.3. By Disorder
    • 18.3.4. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Treatment Type
    • 18.4.3. By Disorder
    • 18.4.4. By Distribution Channel
  • 18.5. Drivers and Restraints: Impact Analysis
  • 18.6. Key Market Participants - Intensity Mapping

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Pricing Analysis, By Competition
  • 19.3. Competition Benchmarking
  • 19.4. Gross Margin Analysis, By Competition
  • 19.5. Competition Developments
  • 19.6. Competition Deep Dive
    • 19.6.1. Vanda Pharmaceuticals Inc.
      • 19.6.1.1. Overview
      • 19.6.1.2. Product and Disorder Portfolio
      • 19.6.1.3. Production Footprint
      • 19.6.1.4. Sales Footprint
      • 19.6.1.5. Strategy
        • 19.6.1.5.1. Marketing Strategy
        • 19.6.1.5.2. Product Strategy
        • 19.6.1.5.3. Channel Strategy
    • 19.6.2. Natus Medical Incorporated
      • 19.6.2.1. Overview
      • 19.6.2.2. Product and Disorder Portfolio
      • 19.6.2.3. Production Footprint
      • 19.6.2.4. Sales Footprint
      • 19.6.2.5. Strategy
        • 19.6.2.5.1. Marketing Strategy
        • 19.6.2.5.2. Product Strategy
        • 19.6.2.5.3. Channel Strategy
    • 19.6.3. Compumedics Ltd.
      • 19.6.3.1. Overview
      • 19.6.3.2. Product and Disorder Portfolio
      • 19.6.3.3. Production Footprint
      • 19.6.3.4. Sales Footprint
      • 19.6.3.5. Strategy
        • 19.6.3.5.1. Marketing Strategy
        • 19.6.3.5.2. Product Strategy
        • 19.6.3.5.3. Channel Strategy
    • 19.6.4. Teva Pharmaceutical Industries Ltd
      • 19.6.4.1. Overview
      • 19.6.4.2. Product and Disorder Portfolio
      • 19.6.4.3. Production Footprint
      • 19.6.4.4. Sales Footprint
      • 19.6.4.5. Strategy
        • 19.6.4.5.1. Marketing Strategy
        • 19.6.4.5.2. Product Strategy
        • 19.6.4.5.3. Channel Strategy
    • 19.6.5. Takeda Pharmaceutical Company
      • 19.6.5.1. Overview
      • 19.6.5.2. Product and Disorder Portfolio
      • 19.6.5.3. Production Footprint
      • 19.6.5.4. Sales Footprint
      • 19.6.5.5. Strategy
        • 19.6.5.5.1. Marketing Strategy
        • 19.6.5.5.2. Product Strategy
        • 19.6.5.5.3. Channel Strategy
    • 19.6.6. Koninklijke Philips N.V
      • 19.6.6.1. Overview
      • 19.6.6.2. Product and Disorder Portfolio
      • 19.6.6.3. Production Footprint
      • 19.6.6.4. Sales Footprint
      • 19.6.6.5. Strategy
        • 19.6.6.5.1. Marketing Strategy
        • 19.6.6.5.2. Product Strategy
        • 19.6.6.5.3. Channel Strategy
    • 19.6.7. Mylan N.V
      • 19.6.7.1. Overview
      • 19.6.7.2. Product and Disorder Portfolio
      • 19.6.7.3. Production Footprint
      • 19.6.7.4. Sales Footprint
      • 19.6.7.5. Strategy
        • 19.6.7.5.1. Marketing Strategy
        • 19.6.7.5.2. Product Strategy
        • 19.6.7.5.3. Channel Strategy
    • 19.6.8. Fitbit, Inc
      • 19.6.8.1. Overview
      • 19.6.8.2. Product and Disorder Portfolio
      • 19.6.8.3. Production Footprint
      • 19.6.8.4. Sales Footprint
      • 19.6.8.5. Strategy
        • 19.6.8.5.1. Marketing Strategy
        • 19.6.8.5.2. Product Strategy
        • 19.6.8.5.3. Channel Strategy
    • 19.6.9. Garmin Ltd
      • 19.6.9.1. Overview
      • 19.6.9.2. Product and Disorder Portfolio
      • 19.6.9.3. Production Footprint
      • 19.6.9.4. Sales Footprint
      • 19.6.9.5. Strategy
        • 19.6.9.5.1. Marketing Strategy
        • 19.6.9.5.2. Product Strategy
        • 19.6.9.5.3. Channel Strategy
    • 19.6.10. Lucimed S.A.
      • 19.6.10.1. Overview
      • 19.6.10.2. Product and Disorder Portfolio
      • 19.6.10.3. Production Footprint
      • 19.6.10.4. Sales Footprint
      • 19.6.10.5. Strategy
        • 19.6.10.5.1. Marketing Strategy
        • 19.6.10.5.2. Product Strategy
        • 19.6.10.5.3. Channel Strategy
    • 19.6.11. RedMed Inc.
      • 19.6.11.1. Overview
      • 19.6.11.2. Product and Disorder Portfolio
      • 19.6.11.3. Production Footprint
      • 19.6.11.4. Sales Footprint
      • 19.6.11.5. Strategy
        • 19.6.11.5.1. Marketing Strategy
        • 19.6.11.5.2. Product Strategy
        • 19.6.11.5.3. Channel Strategy
    • 19.6.12. Compass Health Brands (Carex Health)
      • 19.6.12.1. Overview
      • 19.6.12.2. Product and Disorder Portfolio
      • 19.6.12.3. Production Footprint
      • 19.6.12.4. Sales Footprint
      • 19.6.12.5. Strategy
        • 19.6.12.5.1. Marketing Strategy
        • 19.6.12.5.2. Product Strategy
        • 19.6.12.5.3. Channel Strategy
    • 19.6.13. Beurer GmbH
      • 19.6.13.1. Overview
      • 19.6.13.2. Product and Disorder Portfolio
      • 19.6.13.3. Production Footprint
      • 19.6.13.4. Sales Footprint
      • 19.6.13.5. Strategy
        • 19.6.13.5.1. Marketing Strategy
        • 19.6.13.5.2. Product Strategy
        • 19.6.13.5.3. Channel Strategy
    • 19.6.14. Samarit Medical AG
      • 19.6.14.1. Overview
      • 19.6.14.2. Product and Disorder Portfolio
      • 19.6.14.3. Production Footprint
      • 19.6.14.4. Sales Footprint
      • 19.6.14.5. Strategy
        • 19.6.14.5.1. Marketing Strategy
        • 19.6.14.5.2. Product Strategy
        • 19.6.14.5.3. Channel Strategy
    • 19.6.15. Lanaform N.V.
      • 19.6.15.1. Overview
      • 19.6.15.2. Product and Disorder Portfolio
      • 19.6.15.3. Production Footprint
      • 19.6.15.4. Sales Footprint
      • 19.6.15.5. Strategy
        • 19.6.15.5.1. Marketing Strategy
        • 19.6.15.5.2. Product Strategy
        • 19.6.15.5.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology